February brought policy updates and several biosimilar approvals, including the first FDA approval for an insulin aspart ...
Patients with non-small cell lung cancer (NSCLC) taking bevacizumab biosimilars demonstrated equivalent therapeutic efficacy ...
On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy ...
Number 4: Celltrion expands its reach in Europe, securing marketing authorization from the European Commission (EC) for its denosumab biosimilar candidate (Stoboclo and Osenvelt) and its aflibercept ...
The FDA and European Medicines Agency (EMA) mandate high similarity between biosimilars and reference products, but their ...
Three ustekinumab biosimilars enter the US market, expanding access to more affordable options referencing Stelara ...
Study Confirms CT-P42 Therapeutic Equivalence to Reference Aflibercept in DME ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback